Final Overall Survival and Molecular Analysis in IMmotion151
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma
JAMA Oncol 2021 Dec 23;[EPub Ahead of Print], RJ Motzer, T Powles, MB Atkins, B Escudier, DF McDermott, BY Alekseev, JL Lee, C Suarez, D Stroyakovskiy, U De Giorgi, F Donskov, B Mellado, R Banchereau, H Hamidi, O Khan, V Craine, M Huseni, N Flinn, S Dubey, BI RiniFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.